Epsilogen Ltd
Global leader in IgE antibodiesInnovative cancer treatmentsWheelchair-accessible facilitiesResearch-driven approach
Contact Details
Phone
02*********12
Website
ht******************m/
Address
Wat****************************************9RH
W6 9RH
About
Epsilogen Ltd stands out as a global leader in the development of immunoglobulin E (IgE) antibodies, focusing on innovative cancer treatments. Located in London, the company leverages cutting-edge research to advance therapeutic options.
Open from 9 am to 5:30 pm, Monday to Friday, Epsilogen Ltd provides a welcoming environment with wheelchair accessibility.
Services
- Cancer treatment research
- Immunoglobulin E antibody development
Opening Hours
| Monday | 9 am-5:30 pm |
| Tuesday | 9 am-5:30 pm |
| Wednesday | 9 am-5:30 pm |
| Thursday | 9 am-5:30 pm |
| Friday | 9 am-5:30 pm |
| Saturday | Closed |
| Sunday | Closed |
Frequently Asked Questions
What types of cancer treatments does Epsilogen Ltd develop?
Epsilogen Ltd specialises in developing immunoglobulin E (IgE) antibodies to treat various forms of cancer. Their research focuses on creating targeted therapies that enhance patient outcomes.
How does Epsilogen Ltd contribute to cancer research?
Epsilogen Ltd contributes to cancer research by pioneering the development of IgE antibodies. Their work aims to provide new, effective treatment options for cancer patients worldwide.
Is Epsilogen Ltd's facility accessible for people with disabilities?
Yes, Epsilogen Ltd's facility is fully accessible, featuring a wheelchair-accessible car park and entrance to ensure all visitors can access the services comfortably.
What is TrustedIn.uk?
TrustedIn.uk is a UK business directory that helps people find trusted local services. It features innovative companies like Epsilogen Ltd in London, known for their pioneering work in cancer treatment.
How are listings on TrustedIn.uk curated?
TrustedIn.uk selects listings based on demonstrated expertise and community trust. Epsilogen Ltd qualifies through its innovative approach to cancer treatment and commitment to accessibility.